CO6480960A2 - Composiciones solidas que comprenden ácido 5- aminolevulinico - Google Patents

Composiciones solidas que comprenden ácido 5- aminolevulinico

Info

Publication number
CO6480960A2
CO6480960A2 CO11179486A CO11179486A CO6480960A2 CO 6480960 A2 CO6480960 A2 CO 6480960A2 CO 11179486 A CO11179486 A CO 11179486A CO 11179486 A CO11179486 A CO 11179486A CO 6480960 A2 CO6480960 A2 CO 6480960A2
Authority
CO
Colombia
Prior art keywords
solid
solid compositions
precancerous
ala
cancer
Prior art date
Application number
CO11179486A
Other languages
English (en)
Inventor
Oddveig Sellaeg Helland
Bjorn Klem
Jon Erik Braenden
Aslak Godak
Jo Klaveness
Gry Stensrud
Original Assignee
Photocure Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42628133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6480960(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Photocure Asa filed Critical Photocure Asa
Publication of CO6480960A2 publication Critical patent/CO6480960A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se refiere a composiciones sólidas y a productos farmacéuticos sólidos para su uso en los métodos de diagnóstico fotodinámico del cáncer, las afecciones precancerosas y no cancerosas en la parte inferior del sistema gastrointestinal. Las composiciones farmacéuticas sólidas y los productos farmacéuticos sólidos, comprenden un ingrediente activo que es el ácido 5-aminolevulínico (5-ALA) o un precursor o derivado de 5-ALA o las sales de los mismos farmacéuticamente aceptables. La invención se refiere además a métodos de diagnóstico fotodinámico del cáncer, de afecciones precancerosas y no cancerosas del tracto gastrointestinal inferior, en donde se utilizan las composiciones farmacéuticas y los productos farmacéuticos sólidos.
CO11179486A 2009-06-11 2011-12-27 Composiciones solidas que comprenden ácido 5- aminolevulinico CO6480960A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09251538 2009-06-11

Publications (1)

Publication Number Publication Date
CO6480960A2 true CO6480960A2 (es) 2012-07-16

Family

ID=42628133

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11179486A CO6480960A2 (es) 2009-06-11 2011-12-27 Composiciones solidas que comprenden ácido 5- aminolevulinico

Country Status (18)

Country Link
US (1) US20120134921A1 (es)
EP (1) EP2440188A1 (es)
JP (1) JP2012529451A (es)
KR (1) KR20140014401A (es)
CN (1) CN102802612A (es)
AU (1) AU2010257752B2 (es)
BR (1) BRPI1011650A2 (es)
CA (1) CA2763837A1 (es)
CL (1) CL2011003115A1 (es)
CO (1) CO6480960A2 (es)
CR (1) CR20110649A (es)
MX (1) MX2011013069A (es)
NZ (1) NZ596946A (es)
PE (1) PE20120858A1 (es)
RU (1) RU2527328C2 (es)
SG (1) SG176687A1 (es)
WO (1) WO2010142456A1 (es)
ZA (1) ZA201108850B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107478A1 (en) * 2010-03-01 2011-09-09 Photocure Asa Cosmetic compositions
DE102012105512A1 (de) * 2012-06-25 2014-04-24 Hennig Arzneimittel Gmbh & Co. Kg Arzneiform zur verlängerten Freisetzung von Wirkstoffen
US20140067024A1 (en) 2012-08-30 2014-03-06 Photocure Asa Dual panel photodynamic therapy lamp
GB201221123D0 (en) 2012-11-23 2013-01-09 Photocure As Device for photodynamic treatment
CA2909826A1 (en) * 2013-03-12 2014-10-09 Applied Bioresearch, Inc. Chelation suppository for improved drug delivery
US20170216146A1 (en) * 2014-07-31 2017-08-03 Capsugel Belgium Nv Capsule formulation
JP6588193B2 (ja) * 2014-07-31 2019-10-09 カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップＣａｐｓｕｇｅｌ Ｂｅｌｇｉｕｍ ＮＶ カプセル製剤
US11623008B2 (en) * 2014-08-20 2023-04-11 Professional Compounding Centers Of America Excipient compositions for mucoadhesive pharmaceutical compositions including a synergistic combination of amylopectin, pullulan, hyaluronic acid, and xyloglucan
US9956426B2 (en) 2015-02-26 2018-05-01 Amol Punjabi Upconverting nanoparticles
BR112018011965A2 (pt) * 2015-12-17 2018-12-04 Photocure Asa método de terapia fotodinâmica (pdt) para câncer de bexiga
CN105481946B (zh) * 2015-12-18 2019-05-21 浙江工商大学 5-氨基酮戊酸与3-羟基吡啶-4-酮的缀合物及其制备法和用途
GB201522398D0 (en) 2015-12-18 2016-02-03 Photocure As Device for photodynamic therapy
US10744212B2 (en) * 2016-03-14 2020-08-18 General Electric Company Topical application of nerve labeling dyes for image-guided surgery
GB2546128A (en) * 2016-09-28 2017-07-12 Photocure Asa Pharamaceutical compositions comprising hexaminolevulinic acid and methods of using the same
JP7136807B2 (ja) 2017-04-17 2022-09-13 ザ・ユニバーシティ・オブ・シカゴ ヒトの健康及び疾患の治療用途向けの短鎖脂肪酸の腸への送達用ポリマー材料
CN107434753A (zh) * 2017-07-26 2017-12-05 南京大学 5‑氨基乙酰丙酸及其衍生物的泡腾片及其制备方法
WO2019107389A1 (ja) 2017-12-01 2019-06-06 Ｓｂｉファーマ株式会社 免疫チェックポイント阻害剤による抗腫瘍効果を増強するための医薬組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3181062B2 (ja) * 1991-01-31 2001-07-03 帝國製薬株式会社 下部消化管崩壊経口製剤
US6492420B2 (en) * 1995-03-10 2002-12-10 Photocure As Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
AU708076B2 (en) * 1995-03-10 1999-07-29 Photocure Asa Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
DE69942205D1 (de) * 1998-08-13 2010-05-12 Cima Labs Inc Microemulsionen als feste dosisformen zur oralen verabreichung
ATE314091T1 (de) * 1999-06-09 2006-01-15 Mochida Pharm Co Ltd System für wirkstofffreisetzung im unteren verdauungstrakt
DE10003620A1 (de) * 2000-01-28 2001-08-02 Asat Ag Applied Science & Tech 5-Aminolävulinsäure-Formulierung in nichtwässrigen Lösungsmitteln
GB0018527D0 (en) * 2000-07-27 2000-09-13 Photocure Asa Composition
GB0018528D0 (en) * 2000-07-27 2000-09-13 Photocure Asa Compounds
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US7264629B2 (en) * 2001-11-09 2007-09-04 Qlt, Inc. Photodynamic therapy for the treatment of hair loss
TW577606U (en) * 2001-11-20 2004-02-21 Carry Computer Eng Co Ltd Improved structure of all-in-one silicon disk
DE102005019628A1 (de) * 2005-04-26 2006-11-09 Technische Universität Braunschweig Formulierung zur dermalen Anwendung
GB0609809D0 (en) * 2006-05-17 2006-06-28 Photocure Asa Product
GB0724279D0 (en) * 2007-12-12 2008-01-23 Photocure Asa Use

Also Published As

Publication number Publication date
CL2011003115A1 (es) 2012-06-22
SG176687A1 (en) 2012-01-30
RU2011150920A (ru) 2013-07-20
ZA201108850B (en) 2013-02-27
RU2527328C2 (ru) 2014-08-27
CA2763837A1 (en) 2010-12-16
AU2010257752A1 (en) 2012-01-12
CR20110649A (es) 2012-03-22
EP2440188A1 (en) 2012-04-18
US20120134921A1 (en) 2012-05-31
PE20120858A1 (es) 2012-08-01
NZ596946A (en) 2014-07-25
KR20140014401A (ko) 2014-02-06
CN102802612A (zh) 2012-11-28
MX2011013069A (es) 2012-02-01
WO2010142456A1 (en) 2010-12-16
JP2012529451A (ja) 2012-11-22
BRPI1011650A2 (pt) 2016-03-22
AU2010257752B2 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
CO6480960A2 (es) Composiciones solidas que comprenden ácido 5- aminolevulinico
CY1121107T1 (el) Φαρμακοτεχνικες μορφες δισκιων αμεσης απελευθερωσης
CY1125100T1 (el) Υδατικο φαρμακευτικο σκευασμα ταπενταδολης για απο του στοματος χορηγηση
ES2409069B2 (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
CO6640206A2 (es) Formulación farmaceútica de una solución acuosa de un bufer de ácido glutámico y un anticuerpo
ES2488407T3 (es) Preparación farmacéutica que contiene lipasa de origen bacteriano
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
DOP2013000125A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso.
CO6480932A2 (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida.
CL2009002073A1 (es) Composicion farmaceutica solida para la liberacion controlada de un agente activo activo en el tracto gastrointestinal que comprende al menos un agente acido con solubilidad de menos de 0,3 mg/ml en solucion acuosa a un ph alrededor del pka del agente acido, un polimero hidrofilo, un alcanizador; uso en trastornos cardiovasculares.
BR112015000106A2 (pt) moduladores heterocíclicos de síntes de lipídio
ECSP088414A (es) Derivados de ácido bifeniloxiacético para el tratamiento de una enfermedad respiratoria
AR080491A1 (es) Formulaciones orales y sales lipofilicas de metilnaltrexona
UY32487A (es) Composiciones farmacéuticas de liberación inmediata comprendiendo oxicodona y naloxona
UA105229C2 (uk) Фармацевтичний склад
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
AR069211A1 (es) Derivados de acidos de 1,2,4-oxadiazol ciclobutanoamino carboxilicos, una composicion farmaceutica, proceso de preparacion del compuesto y su uso para preparar medicamentos
ECSP14013275A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
CR20150266A (es) Formulaciones de liberación modificada para oprozomib
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
BR112013000613A2 (pt) composições secas e dispositivos que contêm tais composições secas
BR112014032620A2 (pt) conjugado de nsaid-polímero
EA201270745A1 (ru) Улучшенный стабильный водный состав (e)-4-карбоксистирил-4-хлорбензилсульфона
ECSP088988A (es) Derivados de ácido fenilacético
CO6592037A2 (es) Combinación de un aine y un aminoacido

Legal Events

Date Code Title Description
FC Application refused